Your browser is no longer supported. Please, upgrade your browser.
Enanta Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-3.68 Insider Own1.60% Shs Outstand20.17M Perf Week0.45%
Market Cap828.24M Forward P/E- EPS next Y-5.11 Insider Trans0.00% Shs Float17.88M Perf Month-12.17%
Income-74.00M PEG- EPS next Q-1.28 Inst Own96.60% Short Float9.73% Perf Quarter-16.45%
Sales94.20M P/S8.79 EPS this Y-182.00% Inst Trans-1.10% Short Ratio12.53 Perf Half Y-11.89%
Book/sh21.62 P/B1.94 EPS next Y-27.60% ROA-15.20% Target Price68.14 Perf Year-13.97%
Cash/sh19.06 P/C2.20 EPS next 5Y- ROE-16.20% 52W Range40.32 - 56.97 Perf YTD-0.24%
Dividend- P/FCF- EPS past 5Y-19.60% ROI-9.40% 52W High-26.28% Beta0.38
Dividend %- Quick Ratio16.10 Sales past 5Y-5.30% Gross Margin- 52W Low4.17% ATR1.41
Employees141 Current Ratio16.10 Sales Q/Q-27.20% Oper. Margin-89.90% RSI (14)39.76 Volatility3.21% 3.34%
OptionableYes Debt/Eq0.00 EPS Q/Q-262.60% Profit Margin-78.60% Rel Volume1.00 Prev Close41.02
ShortableYes LT Debt/Eq0.00 EarningsMay 06 AMC Payout- Avg Volume138.87K Price42.00
Recom2.50 SMA20-3.34% SMA50-9.24% SMA200-11.06% Volume138,225 Change2.39%
Jan-29-21Upgrade JP Morgan Underweight → Neutral $55
Nov-24-20Initiated Evercore ISI Underperform $30
Aug-28-20Resumed ROTH Capital Buy $104
Aug-26-20Initiated Piper Sandler Overweight $87
Jul-27-20Upgrade JMP Securities Mkt Perform → Mkt Outperform $70
Mar-17-20Upgrade Robert W. Baird Neutral → Outperform $60
Nov-22-19Downgrade JMP Securities Mkt Outperform → Mkt Perform
Sep-26-19Downgrade JP Morgan Neutral → Underweight $86 → $57
May-24-19Initiated Wolfe Research Outperform $117
Apr-23-19Upgrade Berenberg Hold → Buy $80 → $120
Dec-13-18Initiated Berenberg Hold $80
Jun-06-18Initiated ROTH Capital Buy $133
Feb-08-18Downgrade JP Morgan Overweight → Neutral
Jan-02-18Downgrade RBC Capital Mkts Outperform → Sector Perform
Nov-21-17Reiterated RBC Capital Mkts Outperform $54 → $58
Sep-15-17Initiated RBC Capital Mkts Outperform $54
Jul-11-17Upgrade JMP Securities Mkt Perform → Mkt Outperform
Apr-28-16Downgrade JMP Securities Mkt Outperform → Mkt Perform
Feb-09-16Reiterated Barclays Underweight $16 → $18
Oct-23-15Upgrade JMP Securities Mkt Perform → Mkt Outperform $32
Jul-14-21 05:30PM  
Jun-23-21 02:01AM  
Jun-22-21 04:01PM  
Jun-10-21 07:00AM  
Jun-03-21 07:00AM  
May-11-21 07:00AM  
May-07-21 09:58AM  
May-06-21 05:45PM  
Apr-29-21 07:00AM  
Apr-28-21 12:33PM  
Mar-02-21 07:01AM  
Feb-18-21 04:02PM  
Feb-08-21 11:00PM  
Feb-05-21 10:09AM  
Feb-01-21 04:02PM  
Jan-28-21 12:32PM  
Jan-26-21 07:00AM  
Jan-08-21 07:01AM  
Jan-05-21 07:01AM  
Dec-19-20 10:40PM  
Dec-08-20 07:01AM  
Nov-25-20 12:10AM  
Nov-23-20 10:00PM  
Nov-20-20 10:03AM  
Nov-18-20 07:02AM  
Nov-16-20 07:02AM  
Nov-12-20 12:30PM  
Oct-27-20 09:54AM  
Oct-12-20 01:27PM  
Sep-28-20 07:00AM  
Sep-14-20 07:00AM  
Sep-03-20 07:01AM  
Aug-28-20 06:15AM  
Aug-26-20 09:42AM  
Aug-20-20 07:00AM  
Aug-07-20 09:28AM  
Aug-05-20 01:31AM  
Aug-04-20 06:35PM  
Aug-03-20 07:02AM  
Jul-28-20 12:32PM  
Jul-17-20 01:41PM  
Jul-09-20 07:01AM  
Jun-29-20 07:00AM  
Jun-23-20 12:23PM  
Jun-11-20 07:02AM  
Jun-04-20 10:20PM  
May-23-20 09:58AM  
May-14-20 08:53AM  
May-12-20 07:30AM  
May-09-20 09:43PM  
May-07-20 12:01AM  
May-06-20 06:45PM  
Apr-29-20 12:34PM  
Apr-28-20 04:05PM  
Apr-17-20 10:19AM  
Mar-26-20 04:05PM  
Mar-13-20 07:00AM  
Mar-06-20 07:05AM  
Mar-04-20 08:09AM  
Feb-12-20 12:18AM  
Feb-06-20 05:15PM  
Feb-05-20 04:11PM  
Feb-03-20 07:27AM  
Jan-30-20 12:31PM  
Jan-24-20 07:30AM  
Jan-14-20 05:30AM  
Jan-09-20 07:30AM  
Jan-04-20 08:44AM  
Dec-30-19 07:30AM  
Dec-11-19 11:25AM  
Dec-09-19 07:38AM  
Dec-07-19 11:24PM  
Nov-22-19 08:18AM  
Nov-21-19 05:15PM  
Nov-17-19 08:42AM  
Nov-14-19 10:30AM  
Nov-11-19 10:21AM  
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company offers glecaprevir for the treatment of chronic hepatitis C virus, or HCV under the MAVYRET and MAVIRET names. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Or Yat SunSr. VP & CSOJan 26Option Exercise12.6813,693173,576330,918Jan 28 05:41 PM
MELLETT PAUL JTreasurer and CFOJan 08Sale45.586,000273,46361,759Jan 08 08:57 PM
Gardiner Nathaniel S.Sr. VP & General CounselDec 03Option Exercise30.001,66750,01038,538Dec 07 05:38 PM
MELLETT PAUL JTreasurer and CFONov 11Option Exercise2.543,4808,84946,304Nov 12 04:12 PM
Gardiner Nathaniel S.Sr. VP & General CounselAug 05Option Exercise30.001,66649,98029,271Aug 06 04:38 PM